Year: 2022

news_6

New Data Show Statistically Greater Improvements in Clinical Outcomes with Subcutaneous Infliximab, Compared to Intravenous Infliximab, in Patients With Rheumatoid Arthritis

Presented today at EULAR 2022, data from a new post-hoc analysis show a statistically significant difference in clinical outcomes with...

news_6

Employee Benefits in China, 2022 Update – Key Regulations, Statutory Public and Private Benefits, and Industry Analysis – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Employee Benefits in China, 2022 Update - Key Regulations, Statutory Public and Private Benefits, and Industry Analysis" report...